COVID-19 in Kidney Transplantation: Outcomes, Immunosuppression Management, and Operational Challenges.
Adv Chronic Kidney Dis
; 27(5): 383-389, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-1019900
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2, has led to the death of hundreds of thousands of people worldwide. If infected, older individuals and those with diabetes, hypertension, cardiovascular disease, and compromised immune systems are at higher risk for unfavorable outcomes. These comorbidities are prevalent in patients with kidney disease, hence the significant burden of COVID-19 on kidney transplant programs. Multiple case series of kidney transplant recipients with COVID-19 have shown increased mortality compared to nontransplant patients. To date, we do not have high-level evidence to inform immunosuppression minimization strategies in infected transplant recipients. Most centers however have adopted early antimetabolite withdrawal in addition to other interventions. This review summarizes the published COVID-19 literature as it relates to outcomes and immunosuppression management in kidney transplant recipients. It also discusses challenges pertaining to pretransplant evaluation and wait-listed patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
Telemedicine
/
COVID-19
/
Graft Rejection
/
Immunosuppressive Agents
/
Kidney Failure, Chronic
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Adv Chronic Kidney Dis
Journal subject:
Nephrology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS